Bangladesh Court orders 34 drug firms to halt production, again

By staff reporter

- Last updated on GMT

Bangladesh Court orders 34 drug firms to halt production, again
The High Court in Bangladesh has ordered 34 firms to stop making drugs and recall products after discovering they had ignored a ban imposed in June.

The court issued the order earlier today, explaining that it was prompted by a petition submitted by pressure group Human Rights and Peace for Bangladesh. 

The 34 manufacturers - which make antibiotic active pharmaceutical ingredients (APIs) and or finished drug products - were originally ordered to cease production on June 7​. 

At the time Bangladesh regulator – the Directorate General of Drug Administration (DGDA) – said it had identified breaches of World Health Organisation (WHO) current good manufacturing practices (cGMP) during facility inspections conducted earlier in the year.

Under the original order, 11 of the firms were told to cease manufacturing, had their manufacturing licenses cancelled and were told to recall products.

The remainder of the companies were ordered to halt production and recall their products

Petition

However, according to a petition – no 6969/2016 - submitted by Human Rights and Peace for Bangladesh on July 28, products made by the manufacturers can still be found on pharmacy shelves across the country.

The High Court accepted​ the petition and gave the companies involved until August 18 to cease production.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars